未找到相关数据
A Sickle Sequel: Matthew Porteus Launches Kamau with Positive Nula-Cell Patient Zero Results 12 months after Graphite Bio halted its CEDAR clinical trial for sickle cell disease following an unexpected adverse event in the first patient dosed, follow-up data shows safety and promising gene correction
被引：0
|作者：
Grinstein J.D.
机构：
来源：
关键词：
D O I：
10.1089/genedge.5.1.164
中图分类号：
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：861 / 864
页数：3
相关论文